Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | We’ve announced a £173m investment in the Cancer Research UK Cambridge Institute, following its successful funding review earlier this year. This is the largest single grant we have ever awarded outside of London, positioning the institute as a world leader in cancer research. Over the next seven years, the funding will support the institute’s 300+ researchers in programmes of fundamental discovery science and clinical translational research. Established in 2007, the institute was the UK’s first major new cancer research centre for over 50 years, and the funding will enable researchers to continue to uncover new insights into how cancers develop, grow and spread. “In a golden era for life sciences, this funding bolsters Cambridge as a major global hub for cancer research on an increasingly competitive worldwide stage and will greatly aid the recruitment of top-tier international talent,” says Greg Hannon, Director of our Cambridge Institute. “Research from the institute has already made a positive impact for patients and their families, from the development of innovative technologies, diagnostic tests and advanced imaging methods to the roll out of personalised medicine programmes for those with brain, breast, pancreatic, and ovarian cancers. “We believe that only by embracing the complexity of cancer and how the disease interacts with the normal cells of patients can we move the needle on the hardest to treat cancers.” |
| |
| |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | Applications accepted all year round |
|
---|
| | | | | | Applications accepted all year round |
|
---|
| | | | Applications accepted all year round |
|
---|
| | | | Applications accepted all year round |
|
---|
|
| |
|
|
#ResearchIsBeautiful: calling entries for Lung Cancer Awareness Month |
| Email us your research images today to get shortlisted for our monthly winner. Ahead of Lung Cancer Awareness Month in November, we invite you to share your perspective, your passion and your research into lung cancers with us. All beautiful moments are welcome, from your science to you and your fellow researchers in action as well as the environments where all the amazing research take place. T&Cs apply. |
| |
|
|
|
| | In a recent publication in Cell, researchers from our Brain Tumour Centre of Excellence have found that the adhesion protein integrin-linked kinase (ILK) plays a pivotal role in regulating glioblastoma (GBM) phenotypes, which drive brain tumour progression and therapeutic resistance. Alex Loftus, Margaret Frame (Director of our Edinburgh Centre), Steven Pollard and colleagues at the University of Edinburgh have shown that ILK controls GBM stem cell state and plasticity, in both a GBM stem cell model and patient tumours, through a pathway critically involving STAT3. The study highlights the potential of inhibiting the ILK/STAT3 signalling pathway to suppress the growth of brain cancer. | |
| | | | Researchers have identified significant heterogeneity within Group 3 medulloblastoma, proposing a risk stratification schema to improve treatment. The findings, recently published in NeuroOncology, define very high-risk patients with canonical tumours which are currently incurable, alongside lower-risk groups compatible with longer-term survival. Led by Steve Clifford, Director of Newcastle University Centre for Cancer, the INSTINCT research programme set out to investigate clinicobiological heterogeneity within MYC(N)-amplified medulloblastoma, refining its diagnosis and prediction for the development of new therapies for better outcomes. | |
|
---|
|
|
|
|
| | I really think it can be something that everyone can be a part of. C-Further is not LifeArc's or CRUK's… it's everyone's.” |
| - David Jenkinson, LifeArc It’s never an easy task to bring drugs for childhood cancer forward. After the recent launch of C-Further by us and LifeArc, David Jenkinson, head of childhood cancer at LifeArc reflects on how the initiative might work to lower financial risks, and why you should get involved. |
| |
|
|
---|
|
|
|
|
|
| Let’s talk about… balancing work and family |
| The next session in the "Let’s Talk About..." webinar series will focus on balancing work and family life, offering a platform to share experiences and practical tips and engage in open discussions. During this webinar, you’ll hear from parents at different career stages exploring how they balance work and family. The panel will also discuss how managers and organisations can best support employees preparing for and during parenthood. Join them on 28 October from 12-1pm to ask your questions about how to successfully manage both career and family responsibilities. |
| |
|
|
|
|
|
| Together we are beating cancer |
| | |
---|
|
|
|
| You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here. Your details are safe with us. Check out our Privacy Policy. Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise. This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|